KINDRA CLARK: Open Payments
NPI 1558765727 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,863 in 226 payments from 29 companies in 2025. Trend: 2023 $2,489 · 2024 $4,517 · 2025 $3,863
Food & beverage: $3,863
| Company | Payments | Amount |
|---|---|---|
| Dexcom, Inc. | 13 | $529 |
| Novo Nordisk Inc | 17 | $320 |
| Ascensia Diabetes Care Us Inc. | 36 | $289 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 14 | $277 |
| Corcept Therapeutics | 14 | $271 |
| Amgen Inc. | 16 | $228 |
| Sequel Med Tech, LLC | 24 | $214 |
| Lilly USA, LLC | 9 | $195 |
| Xeris Pharmaceuticals, Inc. | 13 | $180 |
| Mannkind Corporation | 14 | $144 |
Products named: Dexcom G6 Transmitter, JARDIANCE, Korlym, TWIIST, REPATHA, Wegovy, AFREZZA, CeQur Simplicity.
Industry payments across TX — which companies pay providers there.
